FXR agonist 16 

FXR agonist 16 is a FXR agonist with an EC₅₀ of 2.2 μM. FXR agonist 16 activates FXR transcriptional activity, upregulates SHP and BSEP, and downregulates Cyp7a1. FXR agonist 16 exhibits hepatoprotective activity and reduces AST and ALT levels in free fatty acid-induced hepatocellular injury models. FXR agonist 16 can be used for the research of liver injury^[1].

FXR agonist 16 (Compound 3q) (10-100 μM; 24 h) acts as a FXR agonist in stably transfected HEK293 cells, with an EC₅₀ of 2.2 μM^[1].
FXR agonist 16 (1-20 μM; 24 h) exhibits hepatoprotective activity in FFA-injured AML12 cells, reducing liver injury markers without obvious cytotoxicity at concentrations up to 25 μM^[1].
FXR agonist 16 (1-10 μM) modulates FXR downstream target gene expression in AML12 cells, upregulating SHP and BSEP while downregulating Cyp7a1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

372.56

C₂₃H₃₂O₂S

3099198-78-1

CC1(C)[C@]2([H])CC[C@]3(C)CCC[C@](C3)(SC4=C(C(OC)=O)C=CC=C4)[C@@]2([H])C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zou JL, et al. Design, synthesis and biological evaluation of sulfur-containing epicaryolane derivatives as FXR agonists. Bioorg Chem. 2026;170:109531.  [Content Brief]